The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Open accessAbstract
BACKGROUND: There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 study involving 86 patients to compare cisplatin plus gemcitabine with gemcitabine alone. After we found an improvement in progression-free survival, the trial was extended to the phase 3 trial reported here. METHODS: We randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter on days 1 and 8, every 3 weeks for eight cycles) or gemcitabine alone (1000 mg per square meter on days 1, 8, and 15, every 4 weeks for six cycles) for up to 24 weeks. The primary end point was overall survival. RESULTS: After a median follow-up of 8.2 months and 327 deaths, the median overall survival was 11.7 months among the 204 patients in the cisplatin-gemcitabine group and 8.1 months among the 206 patients in the gemcitabine group (hazard ratio, 0.64; 95% confidence interval, 0.52 to 0.80; P<0.001). The median progression-free survival was 8.0 months in the cisplatin-gemcitabine group and 5.0 months in the gemcitabine-only group (P<0.001). In addition, the rate of tumor control among patients in the cisplatin-gemcitabine group was significantly increased (81.4% vs. 71.8%, P=0.049). Adverse events were similar in the two groups, with the exception of more neutropenia in the cisplatin-gemcitabine group; the number of neutropenia-associated infections was similar in the two groups. CONCLUSIONS: As compared with gemcitabine alone, cisplatin plus gemcitabine was associated with a significant survival advantage without the addition of substantial toxicity. Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer. (ClinicalTrials.gov number, NCT00262769.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma
Jarnagin, W. R., Fong, Y., DeMatteo, R. P., Gonen, M., Burke, E. C., Bodniewicz, J., Youssef, M., Klimstra, D., & Blumgart, L. H. (2001) · Annals of Surgery · doi:10.1097/00000658-200110000-00010 · Cited by 1,347
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
Glimelius, B., Hoffman, K., Sjödén, P.-O., Jacobsson, G., Sellström, H., Enander, L.-K., Linné, T., & Svensson, C. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010676 · Cited by 797
Gastrosplenic Fistula From Hodgkin's Lymphoma
Seib, C. D., Rocha, F. G., Hwang, D. G., & Shoji, B. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7695 · Cited by 735
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study
Ortner, M. E. J., Caca, K., Berr, F., Liebetruth, J., Mansmann, U., Huster, D., Voderholzer, W., Schachschal, G., Mössner, J., & Lochs, H. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.07.015 · Cited by 608
PFITZNER, J. (1976) · Anaesthesia · doi:10.1111/j.1365-2044.1976.tb11804.x · Cited by 359
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman, A. M., van Haperen, V. W. T. R., Veerman, G., Kuiper, C. M., & Peters, G. J. (1996) · PubMed · Cited by 304
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Crinò, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.297 · Cited by 303
Valle, J. W., Wasan, H., Johnson, P., Jones, E., Dixon, L., Swindell, R., Baka, S., Maraveyas, A., Corrie, P., Falk, S., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605211 · Cited by 270
Self-citationKornek, G. V., Schuell, B., Laengle, F., Gruenberger, T., Penz, M., Karall, K., Depisch, D., Lang, F., & Scheithauer, W. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh096 · Cited by 143
Ducreux, M. P., Cutsem, E. V., Laethem, J. V., Gress, T. M., Jeziorski, K., Rougier, P. R., Wagener, T., Anak, Ö., Barón, B., & Nordlinger, B. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.026 · Cited by 126
Hansel, D. E., Rahman, A., Hidalgo, M. M., Thuluvath, P. J., Lillemoe, K. D., Shulick, R., Ku, J., Park, J., Miyazaki, K., Ashfaq, R., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63645-0 · Cited by 123
Dingle, B., Rumble, R. B., & Brouwers, M. C. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/565479 · Cited by 57
Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck
Hitt, R., Castellano, D., Hidalgo, M. M., García‐Carbonero, R., Peña, M., Brandariz, A., Millán, J. M., Vincent, J., & Cortés-Funes, H. (1998) · Annals of Oncology · doi:10.1023/a:1008413818569 · Cited by 53
Picking the winners in a sea of plenty.
Scher, H. I., & Heller, G. (2002) · PubMed · Cited by 21
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Self-citationCisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Metadata
- Authors
- Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., Roughton, M., & Bridgewater, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-04-08
- Volume
- 362
- Issue
- 14
- Pages
- 1273-1281
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115261608
- Cited by
- 4,406
- References
- 18
- FWCI
- 123.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.